NorthView Acquisition Corp closes merger with Profusa, Inc., becoming Profusa, Inc.

Profusa, Inc.

Profusa valued at $155M; exchange ratio of 0.94 shares of new common stock per Profusa share.
Issued $10M principal PIPE convertible note to Ascent Partners at 10% OID, 18-month maturity.
Founder shares locked up for 8 months; other lock-up periods from 6 to 12 months.
Profusa is a clinical-stage digital health company with CE-marked Lumee Oxygen and Lumee Glucose in trials.
PIPE Investors subject to lock-up and registration rights; security interest granted on assets.

item 1.01 item 2.01 item 2.03 item 3.02 item 9.01 item 3.03 item 5.01 item 5.02 item 5.06 item 8.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Profusa, Inc.: NorthView ceased to be a shell company upon closing of the business combination.

Change: shell status

Exact text from the filing

NorthView ceased to be a shell company upon the Closing.

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Profusa, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-065686

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.